Business Insider

ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million)

to Close Series B Fundraising with Total of €54 million ($64 million) Marseille, France, September 15, 2020 – ImCheck Therapeutics today announced that it has secured an additional €6 million ($7.1 ...
Business Wire

Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients

SCHLIEREN / ZURICH, Switzerland--(BUSINESS WIRE)--Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the closing of a CHF25 ...
Healio

PulseSight Therapeutics launches with focus on non-viral gene therapies

Please provide your email address to receive an email when new articles are posted on . PulseSight plans to advance therapies for wet and dry age-related macular degeneration. Pureos Bioventures and ...
Morningstar

PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD

Dominik Escher, board director of PulseSight and Partner at Pureos Bioventures, said, “Pureos is delighted to continue its support of PulseSight, to enable it to advance what we believe could be truly ...